MammaPrint и BluePrint (Agendia) – two studies which in combination point towards a therapy choice. They relate to monitoring in early-stage breast cancer
MammaPrint® is an IVD test developed and validated by Agendia (USA). It is based on gene expression profiling in breast cancer. The objective is to stratify patients up to 61 years of age at risk of developing distant metastases within 10 years or within 5 years for patients over 61 years of age. The test is intended for patients with early-stage breast cancer (I or II) and a tumor size of ≤ 5.0 cm.
The results of MammaPrint® are intended for medical professionals as a prognostic marker, in addition to other clinico-pathological characteristics.
What does the MammaPrint results include?
MammaPrint is a test that involves the analysis of 70 genes or biomarkers. These are associated with the risk of developing distant metastases, meaning how likely the cancer is to spread to other parts of the body. Based on the results, patients are grouped into low-risk or high-risk categories.
In patients with the most common form of breast cancer (hormone-positive, HER2-negative, and lymph node-negative), results indicating low risk show a 97.8% probability of no metastases over the next 5 years when hormone therapy is administered alone. In these cases, no significant benefit is observed from adding chemotherapy to the treatment regimen for this group of patients.
In patients whose test results indicate a high risk of developing distant metastases, the combination of hormone therapy and chemotherapy results in a 94.6% probability of remaining metastasis-free over the next 5 years.
All results are based on the MINDACT clinical trial, which successfully groups patients according to their tumor genetic characteristics.
The BluePrint® study involves the analysis of 80 genes, identifying the biological characteristics of individual breast cancer cases. Depending on the obtained results, the tumor is classified into a corresponding subgroup. This is related to information about its behavior and long-term prognosis for response to therapy. Results are obtained within up to 6 days, before a preoperative consultation with a specialist.
Grouping
Luminal type of cancerous growths are developed through the activation of estrogen and progesterone hormonal pathways. This subtype can be further stratified using MammaPrint into luminal A (low risk) and luminal B (high risk) cancers. These luminal subtypes have distinctly different outcomes and thus this information should be incorporated into treatment planning to maximize the likelihood of patient cure.
HER2-positive cancers They are activated mainly by the HER2 pathway. This subtype does not always correspond to HER2 results obtained from immunohistochemistry or FISH analyses, but patients with the HER2 subtype have an excellent response to neoadjuvant HER2-targeted therapy and good long-term outcomes.
Basal cell tumors They are not influenced by hormonal receptors or the HER2 signaling pathway and more closely correspond to clinically triple-negative tumors. This subtype is more aggressive, and patients may benefit from standard or novel therapeutic regimens. Regimens applicable to triple-negative breast cancer. Given the more aggressive nature of these tumors, neoadjuvant therapy may benefit suitable patients compared to adjuvant therapy.
BluePrint® is suitable for breast cancer patients:
- In early stage (stage I, II, or operable stage III);
- With no lymph nodes affected, or with 1 to 3 lymph nodes affected;
- Tumor size up to 5 cm;
- No age limit.
Biological material for analysis: FFPE paraffin block and histological slides
Laboratory Agedia, USA
Test runtime: 10 working days
For more information and details regarding the test, you can call tel. ☎️ 0878 500 730
